Company recognised for sponsor/site relationship quality

LONDON, April 3, 2017– PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organisation, today announced that it was named a top contract research organisation (CRO) in the CenterWatch 2017 Global Investigative Site Relationship Survey. The survey recognises CROs that have high-quality working relationships with investigative sites.

The survey, published today in CenterWatch Monthly, polled over 1,300 global investigative sites on aspects of their relationships with CROs during the past two years. PAREXEL ranked among the top five highest-rated CROs for the overall quality of its direct working relationships with investigative sites. In particular, PAREXEL ranked high in categories such as professional and efficient administrative staff; professional, knowledgeable, and well-trained monitors; understanding of local regulatory/ethics issues; and conduct of clear study initiation visits and training.

“Across the industry, the relationship between CROs and sites has become more strategic. To address this need, we have developed a tailored approach that helps us foster long-term quality partnerships,” said Paul Evans, Corporate Vice President, Global Site Strategy, PAREXEL. “PAREXEL’s high ranking is a reflection of our commitment to our clients and their journeys to bring new treatments to patients in need.”

PAREXEL’s global Site Alliance Network is a significant component of the Company’s approach. The network is comprised of 300 sites with dedicated PAREXEL relationship managers. These individuals also work with key site management organisations (SMOs) to reach an additional 250 sites. The network includes strategic collaborations with Academic Research Organizations on two continents and managed relationships that extend beyond single studies.

PAREXEL continuously solicits feedback from site staff to enhance its support. This enables faster patient recruitment, evaluation, and enrollment in clinical trials. Additionally, the feedback ensures quality and fosters greater collaboration between PAREXEL and sites.

“We focus on simplifying trial execution for busy sites and their staff through our dedicated on-site clinical research associates, office-based monitors, and other support functions,” said Karen Chu, Corporate Vice President, Global Clinical Operations, PAREXEL. “The CenterWatch survey results are a testament to our focus on delivering effective and timely support for our sites and our clients.”

CenterWatch’s 2017 Global Investigative Site Relationship Survey was conducted online between October 2016 and January 2017. The survey included participation from principal investigators, study coordinators, and other clinical research professionals from 1,376 sites. More than 80 percent of the sites were from North America and Europe. The survey, first launched in 1997, uses an instrument to measure sponsor/site relationship quality based on input from representatives from sponsor and CRO companies and investigative sites.